MELANOMA

This early-phase study tested a vaccine (p53MVA) plus the drug pembrolizumab in 11 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to see if the combination is safe and can boost the immune system to attack cancer cells. Participant…

This study tested whether giving the immunotherapy drug pembrolizumab after surgery could delay melanoma from returning in people with high-risk stage III melanoma. About 1,000 participants were randomly assigned to receive either pembrolizumab or a placebo for up to a year. The …

This study tests several combinations of the experimental drug LXH254 in people with advanced melanoma that has a BRAF or NRAS gene change and has stopped responding to prior treatments. The goal is to see if these combos can shrink tumors or slow their growth. About 134 adults a…

This program gives adults with a specific type of advanced melanoma (BRAF mutation-positive) access to two targeted drugs, trametinib and dabrafenib, which work together to shrink tumors and control the disease. It is designed for patients whose cancer has spread or cannot be rem…

This study compares two medications, infliximab and vedolizumab, for treating colitis (colon inflammation) caused by immune checkpoint inhibitor therapy in cancer patients. About 47 adults with genitourinary cancer, melanoma, or non-small cell lung cancer will receive one of thes…

This study looks at how well and how safely two drugs, dabrafenib and trametinib, work together after surgery to stop stage III melanoma from returning in Chinese patients with a specific gene change (BRAF V600). About 78 adults who have had their melanoma completely removed will…

This early-phase study tests a personalized cell therapy for people with certain advanced cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, sarcoma) that carry a protein called MAGE-A4. Patients' own immune cells are genetically modified to recognize and …

This study tests whether adding a new drug called relatlimab to the standard immunotherapy nivolumab helps people with advanced melanoma (skin cancer that has spread or cannot be removed by surgery) live longer without their cancer getting worse. About 714 participants who have n…

This study tests whether combining two immunotherapy drugs (BGB-A445 and tislelizumab) can shrink tumors in people with advanced bladder, kidney, or skin cancer that has spread. About 113 participants who have already tried at least one prior treatment will receive the drug combo…

This study tests an experimental drug (ARRY-614) combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds the safest dose, and the second part checks i…

This early-stage trial tests a new treatment for people with advanced solid tumors (like head and neck, melanoma, or lung cancer). Doctors take a patient's own immune cells from the tumor, grow them into billions, and give them back as a one-time infusion. Some cells are also mod…

This early-phase study tests a treatment called TBI-1301 for people with advanced solid tumors (like sarcoma, melanoma, or ovarian cancer) that have not responded to other therapies. The treatment uses a patient's own immune cells, which are genetically modified in a lab to bette…

This study tests whether combining two immunotherapy drugs (fianlimab and cemiplimab) works better than one drug alone for people with high-risk, removable melanoma. About 151 participants will receive treatment before surgery, then continue after. The goal is to see if the combi…

This early-phase study tests an experimental drug called KIN-2787 in about 400 adults with advanced solid tumors (including lung cancer and melanoma) that have specific BRAF or NRAS gene mutations. The main goals are to check safety, find the best dose, and see if the drug can sh…

This study tests whether a combination of two immunotherapy drugs, nivolumab and low-dose ipilimumab, can prevent melanoma from returning in people who have had surgery to remove stage III or IV melanoma. The treatment is given every few weeks for six months. The main goals are t…

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This study tests whether a new drug, ABP 206, works as well as the approved drug OPDIVO (nivolumab) for people with advanced melanoma that cannot be removed by surgery or has spread. About 633 adults who have not had prior treatment for their advanced melanoma will receive either…

This study tests a new drug, BI-1607, added to two existing immunotherapy drugs (ipilimumab and pembrolizumab) for people with advanced melanoma that has spread or can't be removed. The goal is to see if the combination is safe and helps the immune system fight cancer better. Abo…

This study tests whether adding two experimental vaccines (IO102/IO103) to the standard drug combination of nivolumab and relatlimab can safely shrink tumors in people with advanced melanoma that cannot be removed by surgery. About 43 adults who have not had prior treatment for t…

This early-phase study tests a personalized vaccine (NeoVax) combined with an immune booster (CDX-301) and standard immunotherapy drugs (nivolumab or pembrolizumab) in 10 people with advanced melanoma. The goal is to find the safest dose and see if the vaccine can boost the immun…

This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drugs can shrink tumors. The study involv…

This study tests a combination of three drugs (nivolumab, ipilimumab, and cabozantinib) in people with advanced melanoma that cannot be removed by surgery. The goal is to see if this triple therapy can keep the cancer from growing for at least one year. Participants receive the d…

This study tested whether giving two targeted drugs (dabrafenib and trametinib) for 12 weeks before surgery could shrink melanoma that has spread to lymph nodes. It involved 35 adults with stage IIIB-C BRAF V600 mutation-positive melanoma. The main goal was to see how much cancer…

This study tests a drug called RP1, which is injected directly into skin tumors, for people who have had an organ or stem cell transplant and now have advanced skin cancer. The goal is to see if RP1 can shrink tumors safely without harming the transplanted organ. About 69 partici…

This study tests a treatment for people with advanced melanoma that has spread. Doctors first weaken the immune system with chemotherapy, then give back specially grown immune cells (TILs) to fight the cancer. Some patients also get a dendritic cell vaccine to help the T cells la…

This early-stage trial tests whether adding an experimental treatment (MB097) to a standard immunotherapy (pembrolizumab) is safe and shows signs of working in people with advanced melanoma that did not respond to prior anti-PD1 therapy. About 41 participants will receive the com…

This early-phase study tests a new drug called AB248, alone or with another drug (pembrolizumab), in adults with advanced solid tumors like lung cancer, melanoma, head and neck cancer, and kidney cancer. The main goals are to check safety and find the right dose. About 552 people…

This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent melanoma from coming back in people with high-risk stage II-IV melanoma. About 1,089 participants who have had their melanoma surgically removed will re…

This study tests a new drug called AZD6244 given with standard chemotherapy for people with advanced solid tumors (like breast, colon, lung, melanoma, or kidney cancer) that have no curative options. The main goal is to see if the combination is safe and tolerable, and to find th…

This study tests whether the immunotherapy drug nivolumab, alone or combined with ipilimumab, can shrink melanoma that has spread to the brain. About 76 adults with stage IV melanoma and at least one brain metastasis will receive these treatments. The main goal is to see how many…

This early-phase study tests a drug called veliparib combined with two standard chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors who also have liver or kidney dysfunction. The main goals are to find the safest dose and understand how the body p…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease has progressed after standard immunotherapy. It tests a new drug combination designed to boost the immune system to fight cancer. About 40 participants will receive the experime…

This study tests an experimental drug called INBRX-106, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced solid tumors (like lung, head and neck, melanoma, stomach, kidney, or bladder cancer) that have stopped responding to standard treatment…

This study tests whether adding the drug tocilizumab to the standard immunotherapy combination of ipilimumab and nivolumab can reduce serious immune-related side effects in people with advanced melanoma that cannot be removed by surgery. About 71 participants will receive the thr…

This early-phase study tests a new drug (DKY709) alone or with another drug (PDR001) in people with advanced solid tumors like lung cancer, melanoma, and others that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. About 98…

This study is for people with advanced melanoma that hasn't been treated yet. Researchers are testing whether adding other drugs to pembrolizumab (an immunotherapy) can shrink tumors or stop them from growing. The study involves about 315 participants and focuses on safety and ho…

This study tests a combination of two drugs, dapansutrile and pembrolizumab, in people with advanced melanoma that no longer responds to PD-1 inhibitors. The trial has two parts: first, finding a safe dose of dapansutrile with pembrolizumab, and second, checking if the combo shri…

This study tests an experimental drug called HFB200603, alone or with another immunotherapy (tislelizumab), in adults with advanced solid tumors like kidney, lung, skin, stomach, or colorectal cancer. The goal is to find a safe dose and see how well the body tolerates it. About 8…

This early-phase study tests a new treatment called T-Plex for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack multiple cancer-related targets. Th…

This study tests whether adding two targeted pills (encorafenib and binimetinib) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced melanoma that has a specific BRAF gene change. About 257 adults with untreated, advanced or sp…

This early-phase study tests a new treatment called OBX-115, which uses a patient's own tumor-fighting immune cells that have been modified in the lab to include a protein (IL15) to help them survive longer. These cells are given along with acetazolamide to adults with metastatic…

This study tests a combination of two experimental drugs (zimberelimab and domvanalimab) in 8 adults with advanced melanoma that stopped responding to standard PD-1 inhibitors. The goal is to see if this new combo can shrink tumors or make them disappear. Participants must have t…

This study tests an experimental drug called ensartinib in people with advanced melanoma that has a specific genetic abnormality (ALK alteration). The goal is to see if the drug can shrink tumors or keep them stable for at least 24 weeks. Participants must have already tried othe…

This study tests whether a new combination of two drugs (fianlimab and cemiplimab) works better than the current standard treatment (pembrolizumab) for people with advanced melanoma that cannot be removed by surgery. About 1,500 adults and teens with untreated advanced melanoma w…

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard stereotactic radiation can better control brain metastases that are at higher risk of coming back after radiation alone. About 134 adults with cancers like melanoma, lung, breast, or colorectal cance…

This study tests a drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking these faulty genes. About 534 adults with various cancers, including lung, breast, and br…

This study tests whether giving immunotherapy drugs (nivolumab alone or with ipilimumab) after melanoma surgery can prevent the cancer from coming back. 67 adults with stage III melanoma that can be removed by surgery will receive one dose of nivolumab before surgery, then contin…

This study tests whether the immunotherapy drug nivolumab can prevent melanoma from coming back after surgery in people with stage IIB/C melanoma. About 790 adults and children who had their melanoma completely removed but are at high risk for recurrence will receive either nivol…

This early-phase study tests a new drug, AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment for people with advanced solid tumors that have stopped responding to standard therapies. The main goal is to find the safest dose and check for…

This early-phase study tests a new drug called belvarafenib, alone or with other drugs (cobimetinib and nivolumab), in people with advanced melanoma that has a specific gene change (NRAS mutation) and has stopped responding to standard immunotherapy. The main goals are to check s…

This early-phase study tests a new drug, XL888, added to two existing melanoma drugs (vemurafenib and cobimetinib) for people with advanced BRAF-mutated melanoma that cannot be removed by surgery. The main goal is to find the safest dose of XL888 and see how well the combination …

This early-phase study tests a new treatment called KSQ-001EX for people with advanced solid tumors (melanoma, lung, or head/neck cancers) that have not responded to standard therapy. The treatment involves taking a patient's own tumor-fighting immune cells, modifying them in a l…

This study tests an experimental antibody called GEN1042, alone or with the cancer drug pembrolizumab (with or without chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The goal is to see if the treatment is safe …

This study tests whether adding a personalized cancer vaccine (mRNA-4157) to standard immunotherapy (pembrolizumab) can better prevent melanoma from coming back after surgery. About 267 people with high-risk melanoma that has spread to lymph nodes will receive either the vaccine …

This study tests an experimental drug called HFB200301, alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The main goal is to find safe doses and check for side effects. About 72 people will take part, and the st…

This study compares a new biosimilar drug (GME751) to the standard immunotherapy Keytruda in 322 adults with stage II or III melanoma that has been surgically removed. The goal is to see if the biosimilar is absorbed and works similarly in the body. Participants receive either th…

This early-stage study tests whether a personalized immune cell therapy called TIL is safe and can fight cancer in children, teenagers, and young adults (ages up to 21) with solid tumors that have come back or stopped responding to standard treatments. Participants receive their …

This early-phase study tests a personalized cell therapy (ADP-A2M4CD8) for people with advanced cancers like lung, ovarian, or melanoma that have a specific marker called MAGE-A4. The treatment uses the patient's own immune cells, modified to better attack the cancer, and is give…

This early-phase trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 120 people with various canc…

This study tests whether giving a combination of two immunotherapy drugs (nivolumab and ipilimumab) before surgery can shrink melanoma tumors and prevent the cancer from coming back. About 28 adults with stage III melanoma that can be surgically removed will receive the drugs bef…

This study tests a new imaging technique called MSOT that uses light and sound to create pictures of tumors. About 12 adults with suspicious breast findings or melanoma will get an MSOT scan before their standard biopsy. The goal is to see if MSOT can find tumors and measure oxyg…

This study looks at whether a blood test can find gene changes in lung cancer and melanoma tumors, instead of using a tissue biopsy. The test checks for specific mutations (EGFR, KRAS, BRAF) that help doctors choose the right targeted therapy. About 840 people with these cancers …

This study looks at whether people with certain cancers prefer getting the drug pembrolizumab as a shot under the skin instead of through an IV. About 147 participants will try both methods and report which they like better. The goal is to see if the shot is a more convenient opt…

This study compares two ways of giving high-dose radiation to people with cancer that has spread to bones, spine, soft tissue, or lymph nodes. One schedule gives the radiation in one day, the other over three days. The goal is to see which schedule better controls the cancer in t…

This study looks at whether people with melanoma prefer getting their cancer medicine as a shot under the skin or through an IV drip. About 100 participants will try both methods and report which they like better. The goal is to make treatment more convenient and comfortable.

This early-phase study tests a new type of proton therapy called Pro-GRID for people with large tumors (over 7 cm) that are hard to treat. The goal is to see if the treatment is safe and can be delivered successfully. The study involves 11 adults with sarcoma or melanoma, and foc…

This study looks at two ways to give radiation to people with cancer that has spread to the brain. All participants are also receiving immunotherapy. The standard approach gives a single high dose of radiation, while the experimental approach gives a lower dose over a few days. T…

This study looks back at medical records of 72 American Indian adults with cancers like lung, melanoma, and kidney who received immunotherapy. Researchers compare their outcomes, such as cancer progression and side effects, to those of White patients. The goal is to spot any diff…

This study was designed to look at how community cancer clinics test for biomarkers in common cancers like lung, breast, and colorectal cancer. The goal was to find out if testing is fast and accurate, and to spot any differences in how tests are done. However, the study was with…

This study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…

This study looks at whether a personalized blood test that tracks tumor DNA can help doctors see if melanoma treatment is starting to fail. About 136 adults with stage IIB to IV melanoma will give blood samples while on standard therapy. The goal is to see if changes in the DNA l…

This study looks at how tumors evolve when patients with advanced head and neck cancer or melanoma receive immune checkpoint inhibitors. Researchers collect blood samples and tumor biopsies to track genetic changes in the cancer over time. The goal is to understand how tumors ada…

This study collects white blood cells and tumor cells from up to 7,000 cancer patients and healthy volunteers. The cells are used in the lab to grow large numbers of immune cells that may be given back to patients in future experimental treatments. No direct treatment is provided…

This study looks at whether a high-fiber diet and regular exercise can change the gut microbiome in adults with melanoma who are receiving immunotherapy. Participants are split into two groups: one follows a plant-based diet and exercise plan, the other receives standard guidelin…

This study checks on people with advanced melanoma who previously received a combination of two experimental drugs, fianlimab and cemiplimab. No new treatment is given; instead, researchers track their health, cancer status, and any side effects over time. The goal is to understa…

This study compares a new, faster total-body PET/CT scanner (uEXPLORER) to standard PET/CT scanners in 180 adults with lung cancer, lymphoma, or melanoma. The goal is to find the shortest scan time that still produces clear, high-quality images for cancer staging. Participants wi…

This study collects leftover tissue, blood, and other body fluids from 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples to learn more about what causes these cancers and how to better prevent, …

This study looks back at medical records of children under 18 with advanced melanoma who were treated with the drug ipilimumab. Researchers want to see what serious side effects occurred over time. The goal is to better understand the long-term safety of this treatment in young p…

This study looks at whether a simple blood test that detects tumor DNA can help doctors decide when it's safe for people with advanced melanoma or lung cancer to stop immunotherapy. About 39 patients who have been on treatment for at least a year and show no tumor DNA in their bl…

This early-phase study uses special PET scans to see where two experimental drugs (BI 765063 and BI 770371) go in the body and how much they reach tumors. It includes about 14 adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Par…

This study does not provide new treatment. Instead, it follows up to 1,150 people who previously received experimental cell or gene therapies for cancers like melanoma and neuroendocrine tumors. Participants will have yearly physical exams and blood tests for up to 15 years to mo…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will store and study these samples over time to learn how cancer changes and why some treatments stop working. The goal is to improve future …

This study uses a radioactive antibody (124I-Hu3F8) and PET/CT scans to see how the antibody moves through the body and reaches tumors. Seven people with melanoma, neuroblastoma, or sarcoma will receive one injection and have multiple scans over several days. The goal is to under…

This study looks at whether a simple blood test that finds tiny bits of tumor DNA can catch melanoma coming back earlier than current scans or exams. Researchers will follow 467 high-risk patients who have finished treatment for their primary melanoma. If successful, this approac…

This study is testing a new gene test (Merlin Assay) on tumor samples from 1,820 people with newly diagnosed melanoma. The goal is to see if the test can accurately predict whether the cancer has spread to nearby lymph nodes, which could help some patients avoid an invasive biops…

This study follows about 64,000 adults who grew up on farms to see if early exposure to pesticides and other farm-related factors is linked to cancer. Participants fill out a questionnaire and may provide blood or other samples. The goal is to understand how childhood agricultura…

This study collects leftover tissue and blood samples from people with known or suspected cancer who are already scheduled for surgery or biopsy. Researchers will compare cancerous and normal tissues to find differences that could lead to new treatments. About 1,200 adults aged 1…